Trial Profile

A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary) ; Carboplatin (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Gemcitabine (Primary) ; Letrozole (Primary) ; Paclitaxel (Primary) ; Talimogene laherparepvec (Primary) ; Tamoxifen (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions

21 May 2025 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
11 May 2023 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com